Details of Disease

General Information of Disease (ID: DISSU72Z)

• Disease Name: Ovarian serous adenocarcinoma
• Synonyms: serous ovarian cancer; malignant ovarian serous tumour; serous adenocarcinoma of ovary; ovary serous adenocarcinoma; serous adenocarcinoma of the ovary; serous carcinoma of ovary; serous carcinoma of the ovary; ovarian serous carcinoma; ovarian serous adenocarcinoma
• Definition: An adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that, in well differentiated tumors, resemble the epithelium of the fallopian tube or, in poorly differentiated tumors, show anaplastic features and marked nuclear atypia.
• Disease Hierarchy:
  :
  DISYL50L: Serous adenocarcinoma
  :
  DISSU72Z: Ovarian serous adenocarcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0005211
  UMLS CUI: C1335177
  MedGen ID: 233278

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 21 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
FKBP10	TT4P8O2	Limited	Altered Expression	[1]
RSPO1	TTI9HL4	Limited	Genetic Variation	[2]
AURKB	TT9RTBL	moderate	Altered Expression	[3]
ALK	TTPMQSO	Strong	Altered Expression	[4]
AMOT	TTI48OS	Strong	Biomarker	[5]
BRCA2	TTUARD6	Strong	Genetic Variation	[6]
DYRK2	TT84OS6	Strong	Biomarker	[7]
EPHA5	TTV9KOD	Strong	Altered Expression	[8]
FGFR2	TTGJVQM	Strong	Genetic Variation	[6]
HCN1	TTNB6UQ	Strong	Altered Expression	[9]
KCNH1	TT9XKUC	Strong	Genetic Variation	[6]
LSS	TT7O8ZA	Strong	Genetic Variation	[10]
MUC16	TTC1PS3	Strong	Biomarker	[11]
NACC1	TT4AQ5F	Strong	Altered Expression	[12]
PKN1	TTSL41O	Strong	Altered Expression	[13]
PRKCI	TTWJTHX	Strong	Biomarker	[5]
RSF1	TTMP86V	Strong	Biomarker	[14]
SCN1A	TTANOZH	Strong	Altered Expression	[12]
TK1	TTP3QRF	Strong	Biomarker	[15]
TLN1	TTQSMFG	Strong	Altered Expression	[16]
GABRG3	TTEX6LM	Definitive	Genetic Variation	[17]

This Disease Is Related to 29 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACOXL	OTW680HT	Limited	Genetic Variation	[2]
BABAM1	OTCFPER6	Limited	Genetic Variation	[2]
HNF1B	OTSYIC3T	Limited	Genetic Variation	[2]
HOXD3	OTBUZ35T	Limited	Genetic Variation	[2]
LAMA3	OTFME7HT	Limited	Genetic Variation	[2]
MLLT10	OTURMDV7	Limited	Genetic Variation	[2]
PLEKHM1	OT1SLPGD	Limited	Genetic Variation	[2]
SKAP1	OTD4ZKAL	Limited	Genetic Variation	[2]
TTC28	OTFOOYC3	Limited	Genetic Variation	[2]
ABCA13	OTTHTUQN	Strong	Biomarker	[18]
ANXA4	OTUCRYXL	Strong	Biomarker	[19]
CIAPIN1	OTWS90F9	Strong	Biomarker	[18]
CPEB3	OTP1GQCH	Strong	Altered Expression	[20]
CUEDC2	OTWMOLAJ	Strong	Biomarker	[21]
FRY	OT74IAG2	Strong	Genetic Variation	[6]
KRT8	OTTM4X11	Strong	Genetic Variation	[6]
MAP2K4	OTZPZX11	Strong	Altered Expression	[22]
MTX1	OTLSDNZO	Strong	Genetic Variation	[6]
NEK10	OTN0JAYL	Strong	Genetic Variation	[6]
PAX8	OTRPD9MI	Strong	Biomarker	[23]
PPA1	OTHZK1QB	Strong	Biomarker	[24]
PROK1	OT8S7RUG	Strong	Altered Expression	[13]
RAD51B	OTCJVRMY	Strong	Genetic Variation	[6]
RALY	OT78NNWY	Strong	Genetic Variation	[6]
RBL2	OTBQSOE6	Strong	Biomarker	[25]
SMARCD1	OTHFFT6G	Strong	Biomarker	[26]
ST3GAL1	OTFCO8QX	Strong	Altered Expression	[27]
TBX2	OTTOT7A9	Strong	Altered Expression	[28]
PRPSAP1	OT4PLUU3	Definitive	Genetic Variation	[17]

References

• [1] FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.Int J Oncol. 2013 Mar;42(3):912-20. doi: 10.3892/ijo.2013.1797. Epub 2013 Jan 23.
• [2] Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.
• [3] BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.Virchows Arch. 2014 Jun;464(6):701-7. doi: 10.1007/s00428-014-1577-7. Epub 2014 Apr 23.
• [4] Aberrant Expression of Anaplastic Lymphoma Kinase in Ovarian Carcinoma Independent of Gene Rearrangement.Int J Gynecol Pathol. 2016 Jul;35(4):337-47. doi: 10.1097/PGP.0000000000000260.
• [5] PKC regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
• [6] Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
• [7] Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.Cancer Sci. 2017 Aug;108(8):1565-1573. doi: 10.1111/cas.13280. Epub 2017 Jun 19.
• [8] EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.J Ovarian Res. 2016 Nov 25;9(1):83. doi: 10.1186/s13048-016-0292-1.
• [9] Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1040-6. doi: 10.1111/j.1525-1438.2007.00916.x. Epub 2007 Apr 12.
• [10] MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.Tumour Biol. 2013 Dec;34(6):3501-8. doi: 10.1007/s13277-013-0928-3. Epub 2013 Jul 9.
• [11] Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site.Pathol Oncol Res. 2020 Apr;26(2):1145-1151. doi: 10.1007/s12253-019-00675-4. Epub 2019 Jun 5.
• [12] Nac1 interacts with the POZ-domain transcription factor, Miz1.Biosci Rep. 2014 Jun 5;34(3):e00110. doi: 10.1042/BSR20140049.
• [13] PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.Hum Pathol. 2009 Oct;40(10):1434-40. doi: 10.1016/j.humpath.2009.02.008. Epub 2009 May 7.
• [14] Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability.J Biol Chem. 2010 Dec 3;285(49):38260-9. doi: 10.1074/jbc.M110.138735. Epub 2010 Oct 5.
• [15] Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.Tumour Biol. 2017 Jun;39(6):1010428317706479. doi: 10.1177/1010428317706479.
• [16] miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1.Int J Mol Med. 2013 Aug;32(2):381-8. doi: 10.3892/ijmm.2013.1400. Epub 2013 May 30.
• [17] Identification of novel epithelial ovarian cancer loci in women of African ancestry.Int J Cancer. 2020 Jun 1;146(11):2987-2998. doi: 10.1002/ijc.32653. Epub 2019 Oct 8.
• [18] CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1.
• [19] The role of annexin A4 in cancer.Front Biosci (Landmark Ed). 2016 Jun 1;21(5):949-57. doi: 10.2741/4432.
• [20] miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.J Cell Biochem. 2019 Aug;120(8):12618-12627. doi: 10.1002/jcb.28528. Epub 2019 Mar 4.
• [21] CUEDC2 Contributes to Cisplatin-Based Chemotherapy Resistance in Ovarian Serious Carcinoma by Regulating p38 MAPK Signaling.J Cancer. 2019 Apr 21;10(8):1800-1807. doi: 10.7150/jca.29889. eCollection 2019.
• [22] Homozygous deletion of MKK4 in ovarian serous carcinoma.Cancer Biol Ther. 2006 Jun;5(6):630-4. doi: 10.4161/cbt.5.6.2675. Epub 2006 Jun 9.
• [23] PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.Am J Surg Pathol. 2017 Dec;41(12):1675-1682. doi: 10.1097/PAS.0000000000000935.
• [24] Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.Tohoku J Exp Med. 2017 Feb;241(2):165-173. doi: 10.1620/tjem.241.165.
• [25] Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary.Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):509-11. doi: 10.1097/PAI.0b013e3181e78fe0.
• [26] miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.Hum Pathol. 2017 Dec;70:98-104. doi: 10.1016/j.humpath.2017.10.008. Epub 2017 Oct 24.
• [27] Altered mRNA expressions of sialyltransferases in ovarian cancers.Gynecol Oncol. 2005 Dec;99(3):631-9. doi: 10.1016/j.ygyno.2005.07.016. Epub 2005 Aug 19.
• [28] TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma.Oncol Lett. 2018 Mar;15(3):3085-3090. doi: 10.3892/ol.2017.7719. Epub 2017 Dec 29.